Spyglass Capital Management LLC Cuts Position in Medpace Holdings, Inc. $MEDP

Spyglass Capital Management LLC reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 32.8% during the 3rd quarter, Holdings Channel.com reports. The firm owned 150,882 shares of the company’s stock after selling 73,589 shares during the period. Medpace makes up approximately 4.1% of Spyglass Capital Management LLC’s portfolio, making the stock its 13th largest position. Spyglass Capital Management LLC’s holdings in Medpace were worth $77,577,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. iSAM Funds UK Ltd purchased a new stake in Medpace during the third quarter worth about $149,000. NorthRock Partners LLC purchased a new stake in Medpace during the third quarter worth $473,000. Harvest Fund Management Co. Ltd purchased a new stake in Medpace during the third quarter worth $258,000. Enhancing Capital LLC grew its holdings in Medpace by 4.3% in the third quarter. Enhancing Capital LLC now owns 1,546 shares of the company’s stock valued at $795,000 after purchasing an additional 64 shares during the last quarter. Finally, Johnson Financial Group Inc. boosted its position in shares of Medpace by 115.7% in the 3rd quarter. Johnson Financial Group Inc. now owns 110 shares of the company’s stock worth $57,000 after buying an additional 59 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $450.41 on Friday. The company has a 50-day simple moving average of $523.62 and a 200-day simple moving average of $538.46. The company has a market cap of $12.78 billion, a PE ratio of 29.44, a price-to-earnings-growth ratio of 2.13 and a beta of 1.44. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the prior year, the firm posted $3.67 earnings per share. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MEDP. Truist Financial reduced their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Leerink Partners dropped their price objective on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and lowered their target price for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Finally, Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target for the company in a research report on Tuesday, February 10th. Five analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $486.67.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.